Nuclear Medicine and Biology
Volume 36, Issue 6 , Pages 605-611 , August 2009

Dual-isotope single-photon emission computed tomography for dopamine and serotonin transporters in normal and parkinsonian monkey brains

  • I-Hsun Li

      Affiliations

    • Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan
    • ,
  • Wen-Sheng Huang

      Affiliations

    • Department of Nuclear Medicine, Tri-Service General Hospital, Taipei, 114, Taiwan
    • ,
  • Chin-Bin Yeh

      Affiliations

    • Department of Psychiatry, Tri-Service General Hospital, Taipei, 114, Taiwan
    • ,
  • Mei-Hsiu Liao

      Affiliations

    • Division of Isotope Application, Institute of Nuclear Energy Research, Taoyaun, 325 Taiwan
    • ,
  • Chia-Chieh Chen

      Affiliations

    • Division of Isotope Application, Institute of Nuclear Energy Research, Taoyaun, 325 Taiwan
    • ,
  • Lie-Hang Shen

      Affiliations

    • Division of Isotope Application, Institute of Nuclear Energy Research, Taoyaun, 325 Taiwan
    • ,
  • Jiang-Chuan Liu

      Affiliations

    • Department of Biology and Anatomy, National Defense Medical Center, Taipei 114, Taiwan
    • ,
  • Kuo-Hsing Ma

      Affiliations

    • Department of Biology and Anatomy, National Defense Medical Center, Taipei 114, Taiwan
    • Corresponding Author InformationCorresponding author. Department of Biology and Anatomy, National Defense Medical Center, Taipei 114, Taiwan. Tel.: +886 2 87923300x18749; fax: +886 2 87923159.

Received 8 September 2008 ,Revised 20 January 2009 ,Accepted 16 March 2009.

References 

  1. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999;56:33–39
  2. Uhl GR. Neurotransmitter transporters (plus): a promising new gene family. Trends Neurosci. 1992;15:265–268
  3. Chen YK, Liu RS, Huang WS, Wey SP, Ting G, Liu JC, et al. The role of dopamine transporter imaging agent [99mTc]TRODAT-1 in hemi-parkinsonism rat brain. Nucl Med Biol. 2001;28:923–928
  4. Ma KH, Huang WS, Chen CH, Lin SZ, Wey SP, Ting G, et al. Dual SPECT of dopamine system using [99mTc]TRODAT-1 and [123I]IBZM in normal and 6-OHDA-lesioned formosan rock monkeys. Nucl Med Biol. 2002;29:561–567
  5. Hesse S, Barthel H, Schwarz J, Sabri O, Muller U. Advances in in vivo imaging of serotonergic neurons in neuropsychiatric disorders. Neurosci Biobehav Rev. 2004;28:547–563
  6. Owens MJ, Nemeroff CB. Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem. 1994;40:288–295
  7. Kish SJ. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?. Adv Neurol. 2003;91:39–49
  8. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol. 1991;50:743–755
  9. Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT. J Nucl Med. 2003;44:870–876
  10. Haapaniemi TH, Ahonen A, Torniainen P, Sotaniemi KA, Myllyla VV. [123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord. 2001;16:124–130
  11. Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, et al. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol. 2003;60:1223–1229
  12. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003;28:413–420
  13. Meyer JH, Wilson AA, Ginovart N, Goulding V, Hussey D, Hood K, et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. Am J Psychiatry. 2001;158:1843–1849
  14. Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry. 2004;161:826–835
  15. Rickards H. Depression in neurological disorders: Parkinson's disease, multiple sclerosis, and stroke. J Neurol Neurosurg Psychiatry. 2005;76(Suppl 1):i48–i52
  16. Carson AJ, Ringbauer B, MacKenzie L, Warlow C, Sharpe M. Neurological disease, emotional disorder, and disability: they are related: a study of 300 consecutive new referrals to a neurology outpatient department. J Neurol Neurosurg Psychiatry. 2000;68:202–206
  17. Tucker GJ. Neurological disorders and depression. Semin Clin Neuropsychiatry. 2002;7:213–220
  18. Huang WS, Chiang YH, Lin JC, Chou YH, Cheng CY, Liu RS. Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients. J Nucl Med. 2003;44:999–1005
  19. Dresel SH, Kung MP, Huang X, Plossl K, Hou C, Shiue CY, et al. In vivo imaging of serotonin transporters with [99mTc]TRODAT-1 in nonhuman primates. Eur J Nucl Med. 1999;26:342–347
  20. Huang WS, Lin SZ, Lin JC, Wey SP, Ting G, Liu RS. Evaluation of early-stage Parkinson's disease with 99mTc-TRODAT-1 imaging. J Nucl Med. 2001;42:1303–1308
  21. Huang WS, Ma KH, Chou YH, Chen CY, Liu RS, Liu JC. 99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET. Nucl Med Commun. 2003;24:77–83
  22. Huang WS, Lee MS, Lin JC, Chen CY, Yang YW, Lin SZ, et al. Usefulness of brain 99mTc-TRODAT-1 SPET for the evaluation of Parkinson's disease. Eur J Nucl Med Mol Imaging. 2004;31:155–161
  23. Oya S, Choi SR, Hou C, Mu M, Kung MP, Acton PD, et al. 2-((2-((Dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol. 2000;27:249–254
  24. Ma KH, Huang WS, Huang SY, Cheng CY, Chen CY, Shen LH, et al. Imaging serotonin transporters using [123I]ADAM SPECT in a parkinsonian primate model. Appl Radiat Isot. 2008;66:1799–1803
  25. Huang WS, Ma KH, Cheng CY, Chen CY, Fu YK, Chou YH, et al. Imaging serotonin transporters with 123I-ADAM brain SPECT in healthy non-human primates. Nucl Med Commun. 2004;25:515–519
  26. Scholtissen B, Verhey FR, Steinbusch HW, Leentjens AF. Serotonergic mechanisms in Parkinson's disease: opposing results from preclinical and clinical data. J Neural Transm. 2006;113:59–73
  27. Weng YH, Yen TC, Chen MC, Kao PF, Tzen KY, Chen RS, et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med. 2004;45:393–401
  28. Wang J, Jiang YP, Liu XD, Chen ZP, Yang LQ, Liu CJ, et al. 99mTc-TRODAT-1 SPECT study in early Parkinson's disease and essential tremor. Acta Neurol Scand. 2005;112:380–385
  29. Lu CS, Weng YH, Chen MC, Chen RS, Tzen KY, Wey SP, et al. 99mTc-TRODAT-1 imaging of multiple system atrophy. J Nucl Med. 2004;45:49–55
  30. Kanyo B, Argyelan M, Dibo G, Szakonyi Z, Vecsei L, Fulop F, et al. Imaging of dopamine transporter with Tc99m-Trodat-SPECT in movement disorders. Ideggyogy Sz. 2003;56:231–240
  31. Hwang WJ, Yao WJ, Wey SP, Ting G. Reproducibility of 99mTc-TRODAT-1 SPECT measurement of dopamine transporters in Parkinson's disease. J Nucl Med. 2004;45:207–213
  32. Geng Y, Shi GH, Jiang Y, Xu LX, Hu XY, Shao YQ. Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease. J Zhejiang Univ Sci B. 2005;6:22–27
  33. Newberg AB, Amsterdam JD, Wintering N, Ploessl K, Swanson RL, Shults J, et al. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med. 2005;46:973–977
  34. Berding G, Brucke T, Odin P, Brooks DJ, Kolbe H, Gielow P, et al. [123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy. Nuklearmedizin. 2003;42:31–38
  35. Carvey PM, Punati A, Newman MB. Progressive dopamine neuron loss in Parkinson's disease: the multiple hit hypothesis. Cell Transplant. 2006;15:239–250
  36. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 2004;318:215–224
  37. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. Bioessays. 2002;24:308–318
  38. Przedborski S, Jackson-Lewis V, Naini AB, Jakowec M, Petzinger G, Miller R, et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J Neurochem. 2001;76:1265–1274
  39. Ruffy R, Leonard M. Chemical cardiac sympathetic denervation hampers defibrillation in the dog. J Cardiovasc Electrophysiol. 1997;8:62–67
  40. Bove J, Prou D, Perier C, Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx. 2005;2:484–494
  41. Devous MD, Payne JK, Lowe JL. Dual-isotope brain SPECT imaging with technetium-99m and iodine-123: clinical validation using xenon-133 SPECT. J Nucl Med. 1992;33:1919–1924
  42. Dresel SH, Kung MP, Huang XF, Plossl K, Hou C, Meegalla SK, et al. Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons. J Nucl Med. 1999;40:660–666
  43. Devous MD, Lowe JL, Payne JK. Dual-isotope brain SPECT imaging with technetium-99m and iodine-123: validation by phantom studies. J Nucl Med. 1992;33:2030–2035
  44. Brinkmann BH, O'Connor MK, O'Brien TJ, Mullan BP, So EL, Robb RA. Dual-isotope SPECT using simultaneous acquisition of 99mTc and 123I radioisotopes: a double-injection technique for peri-ictal functional neuroimaging. J Nucl Med. 1999;40:677–684

☆ This work was supported by the Institute of Nuclear Energy Research, National Science Council, and Ministry of National Defense under grants 970945L, NSC 96-2623-7-016-001, and DOD 97-24-02, respectively.

PII: S0969-8051(09)00080-8

doi: 10.1016/j.nucmedbio.2009.03.003

Nuclear Medicine and Biology
Volume 36, Issue 6 , Pages 605-611 , August 2009

Article Tools

* Image Usage & Resolution